Stock Price Movement and Market Context
On 21 Nov 2025, Hikal's stock touched an intraday low of Rs.220.05, representing a fall of 3.7% during the trading session. This decline outpaced the sector's performance, with the stock underperforming the Pharmaceuticals & Biotechnology sector by 2.87% on the day. The stock is currently trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating sustained downward momentum.
In contrast, the broader market benchmark, the Sensex, opened lower by 285.28 points and was trading at 85,288.67, down 0.4%. Notably, the Sensex remains close to its 52-week high of 85,801.70, trading above its 50-day and 200-day moving averages, signalling a generally bullish trend in the wider market despite Hikal's weakness.
Long-Term Price Performance
Over the past year, Hikal's stock has recorded a return of -43.22%, a stark contrast to the Sensex's 10.54% gain over the same period. The stock's 52-week high was Rs.464.50, underscoring the extent of the decline from its peak. This underperformance extends beyond the last year, with the stock also lagging behind the BSE500 index over the last three years and the recent three-month period.
Handpicked from 50, scrutinized by experts – Our recent selection, this Mid Cap from Bank - Public, is already delivering results. Don't miss next month's pick!
- - Expert-scrutinized selection
- - Already delivering results
- - Monthly focused approach
Financial Performance and Profitability Metrics
Hikal's recent financial disclosures reveal a challenging environment for the company. The earnings per share (EPS) have declined by 320.54%, reflecting a significant contraction in profitability. The company reported a net loss after tax (PAT) of Rs. -34.90 crores in the latest quarter, a sharp fall compared to the previous four-quarter average.
Operating profit growth has shown a compound annual growth rate (CAGR) of -16.24% over the last five years, indicating a persistent downward trend in core earnings. The return on equity (ROE) averaged 8.00%, suggesting limited profitability relative to shareholders' funds. Additionally, the return on capital employed (ROCE) for the half-year period stood at 4.44%, one of the lowest levels recorded by the company.
Debt and Interest Coverage
Hikal's ability to service its debt appears constrained, with a Debt to EBITDA ratio of 2.51 times. The operating profit to interest coverage ratio for the quarter was 0.48 times, indicating that operating profits are insufficient to comfortably cover interest expenses. This financial structure may contribute to investor caution and pressure on the stock price.
Valuation and Comparative Analysis
Despite the subdued financial results, Hikal's valuation metrics suggest some degree of attractiveness relative to its peers. The company’s ROCE of 4.1 corresponds with an enterprise value to capital employed ratio of 1.9, which is lower than the average historical valuations of comparable companies in the Pharmaceuticals & Biotechnology sector. This discount in valuation reflects the market’s assessment of the company’s current financial position and growth prospects.
Hikal or something better? Our SwitchER feature analyzes this small-cap Pharmaceuticals & Biotechnology stock and recommends superior alternatives based on fundamentals, momentum, and value!
- - SwitchER analysis complete
- - Superior alternatives found
- - Multi-parameter evaluation
Shareholding and Market Capitalisation
The majority shareholding in Hikal is held by promoters, maintaining a controlling interest in the company. The market capitalisation grade assigned to the company is relatively low, reflecting its current market valuation and size within the Pharmaceuticals & Biotechnology sector.
Summary of Recent Trends
Hikal has declared negative financial results for two consecutive quarters, with profits falling by 86.2% over the past year. The stock’s performance has been below par in both the long term and near term, with returns lagging behind major indices and sector benchmarks. The combination of declining profitability, constrained debt servicing capacity, and subdued market sentiment has contributed to the stock reaching its 52-week low.
Market Outlook and Positioning
While the broader market, as represented by the Sensex, remains near its 52-week high and exhibits bullish technical indicators, Hikal’s stock continues to face downward pressure. The divergence between the company’s share price trajectory and the overall market trend highlights sector-specific and company-specific challenges that have influenced investor sentiment.
Conclusion
Hikal’s stock touching a new 52-week low of Rs.220.05 reflects a period of financial strain and market caution. The company’s recent financial disclosures show significant declines in profitability and challenges in managing debt obligations. Despite some valuation appeal relative to peers, the stock’s performance over the past year and recent quarters indicates a cautious stance by the market. Investors and market participants will continue to monitor the company’s financial metrics and market developments closely.
Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →
